Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "A Phase 1 Study of Fianlimab (anti-LAG-3) + Cemiplimab (anti-PD-1) in Patients With Advanced Melanoma - Poor-Prognosis Subgroup Analysis"
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Inderjit Mehmi
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Inderjit Mehmi
Login to view comments.
Click here to Login
